<DOC>
	<DOC>NCT01021891</DOC>
	<brief_summary>Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere速/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.</brief_summary>
	<brief_title>A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere速/Insulin) in Non-diabetic Patients With &amp; Without Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>Trial objectives are to evaluate the impact of a defined lung disease (COPD) on pharmacokinetic parameters of insulin and fumaryl diketopiperazine (FDKP) after inhalation of Technosphere速/Insulin (T/I), the investigational medicinal product. 40 non diabetic subjects, 20 COPD and 20 age/gender/BMI-matched non COPD subjects will participate in 3 visits: Visit 1 (screening), Visit 2 (subjects will undergo a euglycemic clamp procedure and be dosed with T/I) and Visit 3 (follow up visit).</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male and female subjects minimum 18 and maximum 70 years of age Body Mass Index (BMI) = 36 kg/m2 Subjects with COPD: Diagnosis of COPD (emphysema and/or chronic bronchitis), smoking history =10 years, chronic cough present intermittently or daily with or without sputum and/or dyspnea upon exertion. Subjects with COPD: Pulmonary Function Tests FEV1 =50% (NHANES) III Predicted; FEV1/FVC &lt; 70 % (NHANES) III; TLC =80% of Predicted (ITS) and DLco(unc) =50% of Predicted (Miller) Subjects without COPD: PFTs: FEV1 = 70% NHANES III Predicted; TLC =80% of Predicted (ITS) and DLco(unc) =80% of Predicted (Miller) History of prediabetes or diabetes Previous or current treatment with any antidiabetic drugs Serum creatinine &gt; 2.0 mg/dL in males and &gt; 1.8 mg/dL in females Active smokers defined as having smoked their last cigarette, pipe, and/or cigar without the previous 6 months Previous exposure to any inhaled insulin product or investigational medicines/devices within the previous 30 days prior to entry or participation Clinically significant major organ disease Female subjects of childbearing potential not practicing adequate birth control Subjects with COPD: Significant improvement in preto postbronchodilator spirometry (defined as an increase of 12% AND 200 mL in either FVC or FEV1); Any clinically important pulmonary disease except mild or moderate COPD Subjects without COPD: Any important pulmonary disease confirmed by pulmonary function testing and/or radiologic findings</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Technosphere速 Insulin Inhalation Powder</keyword>
</DOC>